Breast Cancer Symposium to Explore AI Testing
Patients with early-stage breast cancer may hear new data on faster, cheaper digital pathology tests at this year's San Antonio meeting.
Updated on Nov. 2, 2026 in Health

The San Antonio Breast Cancer Symposium, now in its 49th year, will feature research on artificial intelligence and digital pathology in early-stage breast cancer. The five-day meeting is expected to draw more than 11,000 attendees, with co-director Virginia Kaklamani of UT Health San Antonio among those involved.
Why it matters
Digital pathology, which analyzes a photographed image of a tumor specimen rather than shipping the physical tissue to a lab, could make certain tests faster and less costly for patients with early breast cancer. Presentations at the symposium are expected to explore whether this approach can match or exceed information from genomic assays on tumor samples.
The symposium's abstracts and sessions cover AI and digital pathology research in early-stage breast cancer, along with a debate on T-DXd timing for early-stage HER2-positive disease. The projected benefits of faster, cheaper testing remain forward-looking expectations rather than established outcomes.
The players
San Antonio Breast Cancer Symposium
A long-running annual meeting on breast cancer research and treatment, now in its 49th year.
UT Health San Antonio
The academic health system whose affiliated researcher, Virginia Kaklamani, co-directs the symposium.
The details
Digital pathology involves photographing a tissue specimen and transmitting the image electronically for analysis, instead of physically shipping the specimen to a laboratory. The five-day symposium combines educational sessions, state-of-the-art sessions, and debates. Special sessions will address lobular carcinoma, obesity and breast cancer, and GLP-1 agonists, alongside the AI and digital pathology research.
Timeline
The article previewing the symposium was published on November 2, 2026.
The five-day symposium takes place during the scheduled meeting dates.
Health Landscape
The symposium's program reflects a broader move in oncology toward computational tools for analyzing tumor tissue. Digital pathology sits alongside genomic assays as one of several approaches being evaluated for early breast cancer care.
If you are being evaluated for early-stage breast cancer, the symposium's discussions on digital pathology and genomic testing may be worth raising with your oncology team as the field evolves. Ask your physician how tumor testing is handled at your care center and whether any newer methods are an option for you.
The takeaway
Digital pathology and AI are emerging as ways to analyze early breast cancer tissue more quickly and affordably, though their results are still being compared with established tests. Talk with your oncologist about the tumor testing options available to you.
What happens next
The five-day San Antonio Breast Cancer Symposium is scheduled to take place, with more than 11,000 attendees expected.
Further reading
For related coverage, explore Cancer in San Antonio.
Source note: This article includes information reported by MedPage Today.




